Skip to Content
Merck

[Type LADA diabetes--interrogation points].

Przeglad lekarski (2013-06-26)
Ewa Otto-Buczkowska
ABSTRACT

Type LADA diabetes is a form of autoimmune-mediated diabetes in adults. The progression of beta-cell failure is slower than in childhood type 1 diabetes. Patients with LADA present with more preserved beta cell function than those with classic type l diabetes. The diagnosis of LADA according to Immunology Diabetes Society is based on three features: age over 35 years, the presence at least one of four circulating autoantibodies to pancreatic islet cell antigens and lack of requirement for insulin at least 6 month after diagnosis. The level of C-peptide secretion after stimulation with intravenous glucagon administration helped to diagnosis. The optimal treatment of latent autoimmune diabetes in adults (LADA) is not established. Consider that early insulin treatment would result in better preservation of beta-cell function and metabolic control.

MATERIALS
Product Number
Brand
Product Description

Human glucagon, European Pharmacopoeia (EP) Reference Standard